Windlas Biotech shares have gained nearly 9% in the last three months. SEBI-registered analyst Finkhoz is bullish on the stock, driven by its improving fundamental strength and a bullish chart setup. A clean breakout above ₹1,025 will confirm the next strong uptrend. Until then, it remains a “buy-on-dips” candidate, they added.
Let’s take a look at the rationale behind their recommendation.
Fundamental View
Windlas Biotech has demonstrated steady growth over the last two years. Sales have risen from ₹120 crore in June 2022 to ₹210 crore in June 2025, a 75% jump with continuous quarter-on-quarter growth. Its operating profit has also grown from ₹14 crore to ₹27 crore during the same period, while EPS has nearly doubled from ₹4.50 to ₹8.40.
Margins remain stable at 12–13% OPM, and the company continues to operate on a low-debt model, which provides strength during pharma downturns as well.
Technical View
According to Finkhoz, its price action is showing accumulation and strength. The stock has seen strong support near ₹925, its 200-day Exponential Moving Average (EMA). Immediate resistance is pegged at ₹1,025 – a level that has been tested multiple times.
A breakout above ₹1,025 can open the gate to ₹1,160 and higher, according to them. The stock is currently trading above the 50-day EMA (₹967), indicating that the buyers are active on dips.
Windlas Biotech is forming a Cup & Handle pattern on the chart and a breakout above ₹1,025 can open the road towards ₹1,350, they concluded.
News Triggers
The pharma CDMO sector is gaining momentum with PLI scheme tailwinds, and Windlas is a key beneficiary. And according to Finkhoz, Windlas Biotech stands out for its consistent EPS growth and stable margins — making it a steady compounder.
What Is The Retail Mood?
Data on Stocktwits shows that retail sentiment has remained ‘neutral.’
Windlas shares have declined 3% year-to-date (YTD).
For updates and corrections, email newsroom[at]stocktwits[dot]com.